Research
Hormonal
Bupropion/naltrexone combination therapy has questionable cardiovascular safety and modest weight loss effects.
Bupropion/naltrexone is a combination medication that can lead to modest weight loss (4-5%). However, its cardiovascular safety is uncertain, and the trial was terminated early. It is not as effective or safe as newer GLP-1 agonists.
ModerateRefutesMEDIUM confidence
This dual treatment has the potential to reduce body weight 4–5% however its CV safety is questionable. Due to early release of the interim data, the trial was terminated prematurely... they concluded that the CV safety of this drug combination is uncertain.
Why this rating
Based on a prematurely terminated trial with uncertain outcomes.
Source
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Özge Telci Çaklılı et al. · Diabetes Metabolic Syndrome and Obesity · 2023
DOI 10.2147/dmso.s392684
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and dual GLP-1/GIP agonists (tirzepatide 15 mg) produce significant, superior weight loss compared to placebo and older anti-obesity medications.Strong
- Orlistat provides modest weight loss and cardiovascular risk reduction, but its efficacy is heavily dependent on dietary fat restriction.Good
- Phentermine/topiramate combination therapy results in significant weight loss but is associated with increased heart rate and potential psychiatric side effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →